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Helminth parasites are effective in biasing Th2 immunity and inducing regulatory
pathways that minimize excessive inflammation within their hosts, thus allowing chronic
infection to occur whilst also suppressing bystander atopic or autoimmune diseases.
Multiple sclerosis (MS) is a severe autoimmune disease characterized by inflammatory
lesions within the central nervous system; there are very limited therapeutic options
for the progressive forms of the disease and none are curative. Here, we used the
experimental autoimmune encephalomyelitis (EAE) model to examine if the intestinal
helminth Heligmosomoides polygyrus and its excretory/secretory products (HES) are
able to suppress inflammatory disease. Mice infected with H. polygyrus at the time of
immunization with the peptide used to induce EAE (myelin-oligodendrocyte glycoprotein,
pMOG), showed a delay in the onset and peak severity of EAE disease, however,
treatment with HES only showed a marginal delay in disease onset. Mice that received
H. polygyrus 4 weeks prior to EAE induction were also not significantly protected.
H. polygyrus secretes a known TGF-β mimic (Hp-TGM) and simultaneous H. polygyrus
infection with pMOG immunization led to a significant expansion of Tregs; however,
administering the recombinantHp-TGM to EAEmice failed to replicate the EAE protection
seen during infection, indicating that this may not be central to the disease protecting
mechanism. Mice infected with H. polygyrus also showed a systemic Th2 biasing, and
restimulating splenocytes with pMOG showed release of pMOG-specific IL-4 as well
as suppression of inflammatory IL-17A. Notably, a Th2-skewed response was found
only in mice infected with H. polygyrus at the time of EAE induction and not those
with a chronic infection. Furthermore, H. polygyrus failed to protect against disease
in IL-4Rα−/− mice. Together these results indicate that the EAE disease protective
mechanism of H. polygyrus is likely to be predominantly Th2 deviation, and further
highlights Th2-biasing as a future therapeutic strategy for MS.
Keywords: autoimmunity, intestinal nematode, multiple sclerosis (MS), Th2 (type-2) immune responses, cytokine
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INTRODUCTION
Over one-fourth of the global population are infected with
helminth parasites, with the majority of these infections located
within resource-poor tropical countries (1); however before
sanitation improvements and widespread industrialization
occurred within the last century, the prevalence of helminths
was likely to be high across the globe. Helminth parasites
are widely known to induce a state of host immune hypo-
responsiveness that has been associated with a decreased
incidence of inflammatory diseases, a concept that is consistent
with the original “hygiene hypothesis,” which suggested that
increased prevalence of allergy and asthma in industrialized
countries is at least in part due to the reduction in parasitic
burden (2, 3).
Multiple sclerosis (MS) is a severe degenerative autoimmune
disease characterized by lesions in the brain resulting in a range
of symptoms including paralysis, loss of vision and co-ordination
(4). MS is believed to be driven by autoreactive T helper cells,
particularly the Th1 and Th17 subsets, which enter and are re-
activated in the central nervous system (CNS) resulting in the
recruitment of additional T cells and macrophages to establish
inflammatory lesions. These lesions result in loss of myelin,
oligodendrocyte destruction and axonal damage and can account
for the broad range of symptoms seen in patients with MS (5).
While CD4+ T helper cells are well-established as important for
initiatingMS disease; B cells, CD8+ T cells, and natural killer cells
have also been implicated as drivers of disease pathogenesis (6).
The incidence of MS in developed countries is increasing and
a number of reasons have been suggested for this, including a loss
of co-evolved helminth infections (7, 8). Striking evidence for
helminth-induced protection in MS came from an Argentinian
patient cohort that unintentionally acquired gastrointestinal
helminth infection with a variety of species. Those infected
showed a significantly lower frequency of disease exacerbations
and fewer visible lesions on sequential interval MRI scans in
comparison to an uninfectedMS patient cohort (matched for age,
sex, and time since diagnosis of MS) over the same period of time
(9). In addition, after 63 months of follow up, a subset of patients
within the helminth-infected cohort were given anti-parasitic
treatment which lead to an increase in clinical and radiological
disease indicating helminth induced regulatory pathways are
playing a role in disease reduction (10). Following on from these
observational studies several clinical trials were initiated using
Trichiruis suis and Necator americanus, which were chosen due
to their favorable infection safety profile. However, while these
studies confirmed safety, the efficacy of these trials were mixed,
indicating that the context and dose required may differ from
patient to patient, and helminth to helminth (11, 12). Ultimately,
understanding how helminths modulate the immune system
during infection in MS patients will be required if helminth
therapy is to be used more effectively in the future.
To further understand the mechanisms by which helminths
are able to suppress inflammatory diseases, we look to animal
models of infection and disease. Experimental autoimmune
encephalomyelitis (EAE) is a mouse model of MS that is induced
by priming with myelin peptides and/or protein resulting in
CNS-specific pro-inflammatory Th1 and Th17 cells that drive
neurodegeneration (13, 14). In this model, disease is dependent
on Th1 cytokines such as IL-12, and more so on the Th17-
driving cytokine IL-23 (15), as well as GM-CSF and IL-1 (13). In
contrast, Th2 cytokines and regulatory cells (Tregs) are known
to reduce disease severity (16). Helminths are known to strongly
induce Th2 responses and some are associated with increased
Treg numbers, therefore it is unsurprising that mice subjected
to EAE that are simultaneously infected with helminths show a
reduced EAE disease severity compared to non-infected mice, as
comprehensively reviewed by other authors (12, 17).
Helminths employ a range of immune suppressive
mechanisms to enhance their survival within the host such
as expansion of Tregs and myeloid derived suppressor cells
or by releasing factors that can suppress anti-helminthic Th2
immunity. These pathways are also capable of suppressing
bystander inflammation; for example infection of EAE mice with
Schistosoma mansoni induced regulatory macrophages capable
of modulating CNS inflammation (18), whereas immunizing
with egg antigens from either S. mansoni or S. japonicum
suppressed EAE progression by inducing Th2-deviation and IL-4
production, resulting in reduced MOG-specific Th1 and Th17
cytokines (19, 20). In the case of Fasciola hepatica, a reduction
of EAE disease was attributed to TGF-β-induced suppression
of Th1 and Th17 responses and an expansion of Tregs (21).
Infection with a native mouse intestinal helminth parasite,
Heligmosomoides polygyrus, is also associated with an increase in
the number of regulatory T cells as well as strong Th2 responses.
In part H. polygyrus drives Tregs by secreting a protein named
Hp-TGM that mimics the activity of mammalian TGF-β and is
known to induce Tregs in vitro (22). This protein is just one of
many identified from H. polygyrus excretory/secretory products
(HES), from which a number of exciting immune modulating
proteins have been found.
Previous work has identified that infection with H. polygyrus
suppresses EAE disease severity when infection begins after
onset, however the mechanisms by which this suppression is
mediated are not fully defined (23–25). Therefore, this study
aimed to identify the roleH. polygyrus and its excretory/secretory
products play in EAE disease suppression, and whether this
protective effect is mediated through Th2 immune-deviation or
induction of Tregs. We determined that H. polygyrus is able to
ameliorate EAE disease severity in an IL-4Rα-dependent manner
and that protection requires live helminth infection as HES itself
is unable to induce a significant amount of disease protection.
Furthermore, disease protection is associated with increased
Tregs, GATA3+ and ST2+ cells, reduced RORγt+ and IL-17A
cell responses, and a lower level of myeloid cell infiltration into
the CNS.
METHODS
Animals
Female inbred C57BL/6, IL-4Rα−/− (26) and Foxp3-GFP
C57BL/6 reporter (27) mice were used for experiments aged
between 6-14 weeks old. All mice were either bred in-house
or sourced from the University of Edinburgh and housed in
the University of Glasgow animal facility. All experiments were
performed under UK Home Office licence and approved by the
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University of Glasgow and/or University of Edinburgh Ethical
Review boards.
EAE Immunization
Mice were induced for EAE using previously published protocols
(28). In short, an emulsion of MOG35−55 (Genscript, USA)
was prepared in Complete Freund’s Adjuvant (Sigma, USA) and
passed through a 19G needle (BD Biosciences, USA) with glass
syringe until homogenous and opaque. Mice received 100 µl
subcutaneously in each hind limb, followed by 200 ng of pertussis
toxin (Sigma) intra-peritoneally (i.p) in 200 µl of pertussis toxin
buffer (Triton-X 0.017%, Tris pH 7.4 15mM, Sodium chloride
0.5M). On day 2, mice received a repeat dose 200 ng of pertussis
toxin i.p. Mice were monitored closely and weighed daily from
disease onset, EAE mice were scored as previously published
(28), 0 = unaffected; 0.5 = loss of tonicity in the distal region
of the tail; 1 = half-tail paralysis; 2 = full tail paralysis; 3 =
one hind limb paralysis or severe weakness in both hind limbs;
4 = full hind limb paralysis; and 5 = moribund. If any group
in one experiment reached the humane endpoint of severity, all
groups were terminated for analysis, between days 19 and 25
post-EAE induction.
Treatment Regimens
The parasiteHeligmosomoides polygyrus life cycle wasmaintained
through serial passage of CBA x C57BL/6 F1 mice as previously
described (29), and experimental EAE mice received 200 L3
larvae via oral gavage on either the same day as EAE induction or
4 weeks beforehand, as indicated by the Figure legends.Hp-TGM
was prepared as previously described (22) and 1 µg/mouse was
injected intraperitoneally either on days−1, 1, 3, 5 or days 10, 12,
14 as indicated in the Figure legend. Continuous infusion of HES
or PBS via ALZET osmotic minipump (Charles River, UK) using
100 µl capacity (model 1004, 28 days). The minipumps were
primed by incubation with HES or PBS overnight at 37◦C 2 days
before surgical insertion as previously described, and shown to be
effective at immune system modulation over a 14-day period of
release (22).
Parasite Counts
To assess the parasite burden, intestinal adult worms were
counted macroscopically and feces were collected from the mice
from day 14 post-parasite infection. The feces were weighed and
left to soak in 1ml of water for at least 1 h at 37◦C, or overnight
at 4◦C, until soft and then mixed with 1ml of saturated salt
solution (0.27 g NaCl per ml of water). After agitation, samples
were transferred to McMaster chambers and eggs were counted
using a dissecting microscope (Leica, Germany). Fecal counts are
expressed as the number of eggs per mg of feces.
Tissue Isolation and Single Cell
Suspension Preparation
After mice were terminated by CO2 asphyxiation, spleen and
inguinal lymph nodes (iLN) were removed and processed
into a single cell suspension by passing the tissues through a
70µm cell strainer (Greiner Bio-One, Austria), then resuspended
in complete culture medium containing Dulbecco’s minimal
essential medium, supplemented with 100 U/ml penicillin and
100µg/ml streptomycin, 2mM L-glutatmine, 10mM Hepes and
10% heat-inactivated fetal calf serum (FCS) (all from Gibco,
USA). Where needed, red blood cells (RBC) were lysed from
2min at room temperature with 2ml of RBC lysis buffer
(Sigma, USA). Cell viability was calculated using Trypan Blue
exclusion (Sigma) and then resuspended at a concentration of
5 × 106 or 1 × 107 for downstream flow cytometry or MOG-
restimulation, respectively.
Spinal cords were also harvested following perfusion of
the mouse with 20ml of PBS (Gibco). The tissue was then
finely chopped using a scalpel and resuspended in 2.4 mg/ml
collagenase type II (Gibco) and left for 30min in a shaking
37◦C incubator. After incubation, breaking up the clumps by
repeat pipetting with a P1000 pipet and passing through a
70µm cell strainer (Greiner Bio-One) then washing the cells
and resuspending in a 33% Percoll solution [33% Percoll (GE
healthcare, USA), dPBS (Gibco) and HCl to neutralize] and
centrifugation at 760 g for 30min with no brake. The top layer
containing myelin was discarded and the cell pellet resuspended
in a low volume of PBS before flow cytometric analysis.
Flow Cytometry Analysis
Single cell suspensions of spleens, inguinal lymph nodes and
spinal cords were stained using live/dead dye and stained with
fluorescent antibodies before being run on a Celesta or LSRII flow
cytometer (BD Biosciences, USA). Fcγ receptors were blocked
by the addition of purified anti-CD16/CD32 (eBioscience,
USA) as well as the blocking of non-specific antibody binding
by the addition of polyclonal rat IgG (Sigma, USA), before
staining with antibodies to stain extracellular surface markers
including: rat anti-CD4-PerCP/Cy5.5 (clone GK1.5), rat anti-
CD45- PE/cy7 (clone 30-F11), rat anti-CD3-BV711 (clone
17A2), rat anti-PD-1-PE (clone 29F.1A12, Biolegend, USA)
and rat anti-ST2-AF488 (clone RMST2-2) (eBioscience). After
extracellular staining was completed, the cells were fixed and
permeabilised using the Foxp3 transcription factor buffer kit
(eBioscience) as per manufacturer’s guidelines. Antibodies used
to stain transcription factors included: rat anti-RORγt-PE (clone
AFKJS-9), rat anti-Foxp3-eF450 (clone FJK-16s, eBioscience)
and rat anti-GATA3-AF488 (clone 16E10A23, Biolegend). After
acquisition on the flow cytometer, data was analyzed using
FlowJo (BD Biosciences, USA).
ELISA
Splenocytes were resuspended in complete tissue culture media
at a concentration of 1 × 106 cells per well in a 96 well
plate (Corning, USA) in the presence of MOG35−55 peptide
(Genscript, USA) at concentrations ranging between 0.3 and
30µg/ml for 72 h at 37◦C in 5%CO2. The plates were centrifuged
at 400 g for 5min to pellet the cells and supernatants removed and
immediately stored at−80◦C until ELISA analysis. Interleukin
(IL-) 10, IL-4, IL-5, IL-17A and interferon-γ (IFN-γ) sandwich
ELISAs were performed as per manufacturer’s instructions
(eBioscience, USA).
Statistical Analysis
All graphs and data analysis were performed using Prism
(GraphPad, USA).
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RESULTS
Infection With H. polygyrus at Day 0
Reduces EAE Disease Severity
Previous works have shown that infection with 200 L3
H. polygyrus larvae during the chronic phase of EAE is able
to suppress clinical disease within 3–6 days post infection,
indicating that the L4 larvae stage is able to attenuate disease
symptoms and pathology (23, 24). To investigate further the
impact of adult H. polygyrus on EAE, mice were infected
on the same day as the EAE immunization protocol, which
results in adult worms being present in the small intestine
during the onset of EAE disease (days 10–14). Mice infected
with H. polygyrus showed a significant amelioration in disease
severity, and a 4-day delay in weight loss (Figures 1A,B).
Additionally, the reduction in disease symptoms in H. polygyrus-
infected mice correlated with reduced CD4+ T cell (Figure 1C,
Supplementary Figure 1A) and macrophage (Figures 1D,E,
Supplementary Figures 1B and 2) infiltration into the spinal
tissue, confirming that parasite infection impedes EAE disease
progression in the CNS.
Infection with H. polygyrus was also found to alter the T cell
immune profile in the periphery, resulting in localized alterations
in major subpopulations. In the (hind limb-draining) inguinal
lymph nodes, there was a significant increase in T regulatory
cell (Treg) frequency (Figure 2A), and while no change was seen
in cells expressing the disease-driving Th17 cell marker RORγt
(Figure 2B), cells expressing the Th2 marker GATA3 trended
toward an increase (Figure 2C). In the spleen, despite no increase
in Tregs (Figure 2D), there was a marked effector T cell skewing
with reduced RORγt Th17 (Figure 2E) and expanded GATA3+
Th2 (Figure 2F, Supplementary Figure 3).
The shift in effector response mode was even more marked
in autoantigen-specific assays, as upon restimulation with the
immunizing peptide pMOG35−55, the splenocytes from H.
polygyrus-infectedmice secreted lower levels ofMOG-specific IL-
17A and higher levels of IL-4, whilst MOG-specific IFN-γ was
similar between infected and control EAE mice (Figures 2G–I).
Overall, these results suggest that infection with H. polygyrus
induces immunological changes that can mitigate EAE disease,
however whether the parasite infection is driving these changes
or if the proteins secreted by the adult worm are responsible had
yet to be determined.
H. polygyrus Excretory/Secretory Product
Marginally Delays EAE Onset
Like many helminth parasites, H. polygyrus is known to secrete
a number of proteins with immunosuppressive properties (30),
and hence we next investigated whether proteins secreted by
H. polygyrus adult worms are able to suppress EAE disease.
As mice infected with H. polygyrus showed a significant
increase in the frequency of Tregs in the inguinal lymph nodes
(Figure 2A), we first hypothesized that one mechanism by which
the parasite is offering protection is through the induction of
Tregs. Recent studies in our lab have identified a protein, Hp-
TGM, secreted by H. polygyrus that is able to induce de novo
Tregs by mimicking the action of TGF-β (22). We therefore
next tested if administration of this protein can induce Tregs
and suppress EAE symptoms. However, when Hp-TGM was
administered either during disease induction (Figure 3A) or
disease onset (Figure 3B), no protection was seen compared to
untreated EAE mice. However, we also did not see an expansion
of Tregs in either the inguinal lymph nodes (Figures 3C,D)
or spleen (Figures 3E,F), suggesting that if Treg induction
is the mechanism by which H. poygyrus suppresses disease,
adminstration ofHp-TGM in this way is not effective at inducing
Tregs in this model.
Further, we aimed to assess whether the whole H. polygyrus
excretory/secretory product, HES, can suppress EAE symptoms.
To do this, HES was collected from adult H. polygyrus as
previously described (29) and continuously administered into
the peritoneal cavity by osmotic minipumps that were surgically
implanted 2 days prior to immunization with pMOG (for
initiation of EAE). While HES minipumps only resulted in a
slight delay of EAE disease symptoms compared to control
sham surgery mice (Figure 4A), there was a significant reduction
in the number of cells in the inguinal lymph nodes and a
trend to reduction in the spleen (Figures 4B,C), which indicates
that HES reduced the local inflammation but could only delay
progression of the disease. No significant changes were seen
in Treg frequencies in either the lymph node (Figure 4D) or
spleen (Figure 4E). Treatment with HES significantly increased
the proportion of ST2 expressing CD4+ T cells in both the
lymph node and spleen, indicating an induction in Th2-type cells
(Figures 4F,G). There was also evidence for higher expression
of PD-1, in the spleen alone (Figures 4H,I) suggesting that
HES-treated mice had a immunological shift toward a more
suppressive Th2-type response which is associated with a reduced
EAE disease severity.
An immune deviation effect was further supported by the
responses of splenocytes restimulated in vitro with pMOG, in
which HES-treated mice produced lower levels of the disease-
driving cytokine IL-17A (Figure 4J), with some suggestion of
elevated IL-5 (Figure 4K), a surrogate Th2 cytokine in this
experiment. Altogether these results indicate that treating mice
with HES during the early EAE induction phase leads to no more
than a marginal delay in disease symptoms, perhaps through a
modest reduction of cell infiltration to the lymph nodes that drain
the site of immunization and dampening of inflammatory IL-17A
cytokine responses.
Together the results from Hp-TGM and HES administration
during EAE indicate that proteins secreted by the parasite may
only play a small role in EAE disease suppression byH. polygyrus,
and that the immune response to the parasite itself may be
more crucial.
Early but Not Chronic Infection With
H. polygyrus Is Able to Suppress EAE
Because H. polygyrus infection on the day of EAE induction
protects against disease, while adult secreted immunomodulatory
products do not, we postulated that a key factor may be the early
events following parasite entry into the intestinal tract. Here,
larvae invade the duodenal submucosa for ∼7 days, where they
molt twice and grow to the adult stage that regains the lumen
by day 8, having stimulated a potent type 2 response in the
tissues. We therefore compared mice infected, as previously, at
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FIGURE 1 | H. polygyrus suppresses EAE disease in mice infected on the day of immunization. Female C57BL/6 mice were immunized for EAE on day 0 and were
either left untreated (EAE), or received 200 L3 H. polygyrus larvae also on day 0 (EAE + Hp). (A) Disease score (see Methods). (B) Weight change. (C) Spinal cord
CD4+ T cell infiltration at euthanisation on day 19. (D) Spinal cord macrophage infiltration (CD11b+CD45hi cells as gated in (E) and detailed in
Supplementary Figure 1) at euthanisation on day 19. (E) Within the gate of live single leukocytes, CD45+ spinal cord cells were further gated into non-myeloid cells
(CD45hiCD11b−), microglia (CD45intCD11b+), and infiltrating macrophages (CD45+CD11b+) as detailed in Supplementary Figure 2. Plots shown are taken from
individual mice with median values in (D). Data are pooled from two independent experiments, with a total n = 10, and show arithmetic means and standard errors.
Data were analyzed by 2-way ANOVA with Sidak’s multiple comparisons test (A,B) or by Mann–Whitney non-parametric test (C,D), *p < 0.05, **p < 0.01.
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FIGURE 2 | Modes of immune response shift following H. polygyrus infection. Female C57BL/6 mice were immunized for EAE on day 0 and were either left untreated
(EAE), or received 200 L3 H. polygyrus larvae also on day 0 (EAE + Hp). (A) Foxp3+ Tregs in draining inguinal lymph nodes (LNs), measured by flow cytometry at
euthanisation on day 19. (B) Percentage of CD4+ T cells expressing the Th17 cell marker, RORγt, in inguinal lymph nodes. (C) Percentage of CD4+ T cells expressing
the Th2 marker, GATA3, in inguinal lymph nodes. (D) Percentage of Foxp3+ Tregs in the spleen. (E) Percentage of RORγt+ Th17 cells in the spleen. (F) Percentage of
GATA3+ Th2 cells in the spleen. (G) MOG-specific responses of spleen cells, IFNγ measured by ELISA in supernatants 72 h post culture. (H) MOG-specific responses
of spleen cells, IL-17A. (I) MOG-specific responses of spleen cells, IFNγ. All data are pooled from two independent experiments, with a total n = 10, except for (C) in
which n = 6, and shown are the means ± SEM; (A–F) were statistically analyzed by unpaired t-tests with Welch’s correction is SDs were not equal; (G–I) were tested
by 2-way ANOVA with Bonferroni’s mulitple comparisons tests. *p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 3 | H. polygyrus Transforming Growth Factor-β Mimic (Hp-TGM) does not protect mice from development of EAE. Female C57BL/6 mice were immunized for
EAE on day 0 and were either left untreated (EAE) or received Hp-TGM (EAE + Hp), spleens and inguinal lymph nodes were assessed for Treg populations at
euthanisation at days 19 (A,C,E) or 21 (B,D,F). (A) Hp-TGM was given on days −1, +1, 3, and 5 relative to EAE induction, as indicated by the black arrows. (B)
Hp-TGM was given on days +10, 12, and 14 relative to EAE induction, as indicated by the black arrows. (C) Foxp3+ Tregs as percentage of all inguinal lymph node
CD4+ T cells from mice in (A), as measured by flow cytometry at euthanisation. (D) Foxp3+ Tregs as percentage of all inguinal lymph node CD4+ T cells from mice in
(B). (E) Foxp3+ Tregs as percentage of all splenic CD4+ T cells from mice in (A). (F) Foxp3+ Tregs as percentage of all splenic CD4+ T cells from mice in (B). Data in
(A, B) each represent individual experiments with no statistical differences between groups, n = 5 at the start of both experiments however 2 mice in each group from
experiment graphs in (B) were culled due to experimental endpoints being reached.
the time of EAE induction, with animals that had been infected
28 days earlier, a timepoint known to be immunoregulatory in
other models such as airway allergy (31).
When mice infected at the different time points were
compared for the course of disease, it was clear that animals
bearing a chronic infection showed little protection against
disease, unlike mice that were infected on the day of EAE
induction and experiencing the early, tissue-invasive phase of
infection (Figure 5A). As previously, co-incident infection with
EAE induction reduced cell infiltration into the inguinal lymph
nodes (Figure 5B), and increased Treg frequencies (Figure 5C),
neither of which were observed in chronically-infected mice.
More notably, the pMOG-specific cytokine responses of spleens
from mice infected 28 days prior to EAE induction did not differ
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FIGURE 4 | H. polygyrus ES administration delays but does not prevent EAE. Female C57BL/6 mice were immunized for EAE on day 0 and received either a sham
surgery (EAE) or Alzet mini-osmotic pump surgically implanted i.p, releasing HES at a continuous rate of 0.25 µl per h for 14 days (EAE + HES). (A) HES was given by
intraperitoneal osmotic minipump 2 days prior to EAE induction. (B,C) Total cell numbers in inguinal lymph node (B) and spleen (C) at day 22. (D,E) Foxp3+ cell
frequencies in inguinal lymph node (D) and spleen (E). (F, G). ST2+ T cell frequencies in inguinal lymph node (F) and spleen (G). (H,I) PD-1+ T cell frequencies in
inguinal lymph node (F) and spleen (G). (J) MOG-specific responses of spleen cells, IL-17A measured by ELISA at day 22. (K) MOG-specific responses of spleen
cells, IL-5. Data are from one of two similar independent experiments, with n = 6 per group per experiment; (A,J,K) were tested by 2-way ANOVA with Bonferroni’s
mulitple comparisons tests. (B–I) were statistically analyzed by unpaired t-tests with Welch’s correction if SDs were not equal. Shown are the means ± SEM and
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
significantly from the uninfected group, while simultaneously-
infected mice showed a significant reduction in pMOG-specific
IL-17A and sharply elevated pMOG-specific IL-4 responses
(Figures 5D,E). These results indicate that H. polygyrus is most
able to suppress EAE disease during the tissue-invasive stages
of infection and during this phase MOG-specific T cells are
polarized toward the Th2 mode which has been found to offer
protection in previous studies of the EAE model (19, 20).
H. polygyrus Disease Suppression Is
IL-4Rα-Dependent
In view of the marked skew toward Th2 during EAE in mice
infected with H. polygyrus, including induction of pMOG-
specific IL-4 responses, we aimed to assess whether signalling
through the IL-4Rα plays a critical role in EAE disease
suppression by this helminth. We therefore tested mice that
were deficient for IL-4Rα (IL-4Rα−/−), the shared receptor
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FIGURE 5 | Early, but not chronic, H. polygyrus infection is required to inhibit EAE. H. polygyrus infection was administered 28 days prior to, or on the day of EAE
induction. Female C57BL/6 mice were immunized for EAE on day 0 and were either left untreated (EAE), or received 200 L3 H. polygyrus larvae also on day 0 (EAE +
Hp D0), or on day−28 (EAE + Hp D-28) prior to EAE immunization. (A) Disease course in mice with EAE with or without H. polygyrus infection at d0 or day−28. (B)
Total cell numbers in inguinal lymph nodes at day 19. (C) Foxp3+ cell frequencies in inguinal lymph node. (D) MOG-specific responses of spleen cells, IL-17A
measured by ELISA on day 19. (E) MOG-specific responses of spleen cells, IL-4. All data are pooled from two independent experiments, with a total n = 10, and
shown are the means ± SEM; (A) was tested by mixed-effects analysis with a multiple comparisons post-tests. (B,C) were tested by 1-way ANOVA with Tukey’s
multiple comparisons tests. (D,E) were tested by 2-way ANOVA with Bonferroni’s multiple comparisons tests. Shown are the means ± SEM *p < 0.05, **p < 0.01.
component that transduces signals for both IL-4 and IL-13. In
these gene-targeted mice,H. polygyruswas unable to significantly
suppress EAE disease unlike C57BL/6 wild-type control mice
(Figure 6A) even though their worm load was slightly higher
(Figure 6B) and this lack of protection was accompanied by
minimal Th2 and ST2+ CD4T cell expansion compared to
wild-type mice (Figures 6C,D). However, both IL-4Rα−/− and
C57BL/6 mice showed an increase in PD-1+ CD4T cells with
H. polygyrus infection, suggesting that despite their association
with immune down-regulation, this cell subset is not involved
in dampening EAE in this model (Figure 6E). Neither genotype
showed any rise in Treg frequency at this time-point (day 26 post-
infection), and while the baseline Treg proportions were actually
higher in IL-4Rα−/− mice (Figure 6F), there was no correlation
with protection, as disease severity was similar between IL-
4Rα−/− and wild-type mice. Together, these results indicate that
the ability to mount a strong Th2 response to H. polygyrus is
central to the suppression of EAE disease by the parasite, and
the timing of the anthelminthic Th2 response is pivotal for
suppression of disease.
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FIGURE 6 | H. polygyrus fails to protect against EAE in IL-4Rα-deficient mice. Female C57BL/6 or IL-4Rα-deficient mice were immunized for EAE on day 0 and were
either left untreated or received 200 L3 H. polygyrus larvae also on day 0 (+Hp). (A) Disease course of EAE in uninfected and infected C57BL/6 wild-type and
IL-4Rα-deficient mice. (B) Adult worm burdens in infected C57BL/6 wild-type and IL-4Rα-deficient mice at the time of euthanisation, day 26. (C) Frequency of CD4+
T cells expressing the Th2 marker, GATA3, in spleen at day 25 as measured using flow cytometry. (D) Frequency of CD4+ T cells expressing ST2 in spleen. (E)
Frequency of CD4+ T cells expressing PD1 in spleen. (F) Frequency of Foxp3+ Tregs in the spleen. Data are from one of two similar independent experiments with
n = 4–6 per group; (A) was tested by a 2-way ANOVA with Bonferroni’s multiple comparisons test. (C–F) were statistically analyzed by unpaired t-tests with Welch’s
correction if SDs were not equal. Shown are the means ± SEM and *p < 0.05 and ****p < 0.0001.
DISCUSSION
Helminth parasites have been hypothesized as important
environmental regulators for immune tolerance in both model
systems and in human populations (2, 17, 32), resulting in
numerous studies assessing the use of helminths or their products
as therapeutic agents in the fight against autoimmune disease.
In the current study we used a natural mouse parasite H.
polygyrus, a model for human intestinal helminth infection,
to understand the mechanism(s) by which helminths are able
to suppress an animal model of multiple sclerosis with the
aim to further understand the immune pathways involved in
suppressing autoimmune disease.
Infection with H. polygyrus is known to induce many
immunoregulatory pathways including Tregs, alternatively
activated macrophages and regulatory dendritic cells, as well
as regulatory B cells acting through IL-10 (33), suggesting
various potential mechanisms by which H. polygyrus is capable
of ameliorating inflammatory diseases (34). Here we show that
infection with H. polygyrus protects mice from developing
severe EAE and that this disease suppression is in fact mediated
through IL-4R signaling and Th2 immune deviation rather
than a Treg mechanism, as IL-4Rα−/− mice infected with
H. polygyrus developed EAE symptoms similar to uninfected
mice. We also show that some of this protection is not limited
to infection with the live parasite, as administration of the
excretory/secretory product, HES, is able to delay disease onset.
Although these mice do succumb to EAE, they also show reduced
cell infiltration in the immunization draining lymph nodes and
reduced pMOG-specific IL-17A release.
Interestingly, chronic H. polygyrus infection (day 28) prior to
EAE induction was not protective, althoughmay limit the disease
severity which indicates active immune deviation to Th2 may be
essential to suppress developing Th17/Th1 responses in the EAE
model. Furthermore, day 28 of infection coincides with adult H.
polygyrus residing in the gut, where they secrete HES proteins,
therefore these results are consistent with HES administration
only having a limited effect on the EAE disease severity. In
contrast, our finding that protection coincides with the early
stages of active infection are consonant with recent reports from
another laboratory, that infection of mice at the peak of EAE
disease results in a rapid amelioration of symptoms, accompanied
by evidence of downregulation within the myeloid compartment
(24, 25). During the initial 7 days of infection, serum IL-4 reaches
a peak and declines thereafter (23), supporting our findings
that the early phase of infection is the most protective. Further,
type 2 innate lymphoid cell (ILC2) responses are at their most
prominent in early infection (35, 36), and IL-4/IL-13 from this
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subset is likely to contribute to the Th2 skewing observed in
our model.
Our results are also consistent with other helminth infections
that have been shown to potently modulate EAE such as S.
mansoni (18), T. peusdospiralis (37), F. hepatica (21), Trichinella
spiralis (38), and Taenia crassiceps (39) with protection in these
infections mostly being attributed to Th2 immune deviation
and suppressed levels of pMOG-specific TNF, IFN-γ, and IL-
17A. These studies also highlighted other cell populations as
potential suppressors of T cell activation such as alternatively
activated macrophages (AAM) and myeloid-derived suppressor
cells (MDSC) that regulate CNS infiltration and EAE progression.
DuringH. polygyrus infection AAMare induced by Th2 cells after
epithelial damage alerts the immune system of parasite infection,
resulting in IL-4 release (40) and phenotypic shifts in both
peritoneal and CNS macrophage populations (25). It is therefore
possible that myeloid cells are also crucial for EAE protection
with H. polygyrus as it is known that AAM and MDSCs are able
to ameliorate EAE (41, 42) and therefore this may be one of the
ways in which IL-4 signaling is protective inH. polygyrus-infected
EAE mice.
In some instances the suppressive effect of helminth infection
on EAE can be mimicked by the parasites’ excretory/secretory
products (ES). However, in the current study we found HES was
only able to delay disease onset indicating that the immunological
changes produced by HES were not strong enough to recapitulate
the effect seen with live parasite infection. In contrast, a study
with Taenia crassiceps ES (TcES), which showed that in addition
to Th2-deviation, ES was able to sequester inflammatory cells
into the periphery and therefore inhibit the induction of EAE
by preventing trafficking of cells to the CNS (43), a mechanism
that could well underpin the protective ability of liveH. polygyrus.
Soluble egg antigens (SEA) from S. japonicum and T. spiralis ES
also ameliorate EAE disease in a way that was similar to whole
parasite infection, protection that was related to a Th2 shift in
both the periphery and CNS (19, 44).
Although HES treatment in our study did not offer long-
term protection from EAE, a significant reduction in pMOG-
specific IL-17A indicated that some aspects of autoimmunity are
suppressed, although overall disease symptoms eventually appear
regardless. Consistent with HES, a moderate reduction in IL-17A
was seen in mice with a chronic H. polygyrus infection where
adult H. polygyrus parasites would be present in the intestine
secreting the HES products, indicating these ES proteins alter
the autoimmunity status of cells in the periphery but ultimately
disease symptoms progress. Interestingly, IL-17A is thought to
downregulate the tight-junction proteins therefore increasing the
permeability of the BBB and allowing CNS infiltration to occur
(45). In addition, IL-17A is also thought to recruit activated
neutrophils and monocytes into the CNS, facilitating further
damage and demyelination which exacerbates symptoms of EAE
disease further (46). Given that HES and chronically infected H.
polygyrus mice had a reduced IL-17A response and a delay or
slight reduction in EAE symptoms in our study, it is possible
that this reduction suppressed early EAE disease and was then
overcome as disease progressed further. It is also possible that the
lack of efficacy in our study may be due to the dose of HES used,
we chose 2 µg/mouse/day by continuous infusion while other
studies administered up to 250 µg of protein by subcutaneous
or intraperitoneal injection every other day (43, 47, 48).
While many studies have identified Th2-immune deviation
as the dominant mechanism by which helminths suppress EAE
disease, there is also mounting evidence that IL-33 signaling also
plays a central role. One study looked at the role of the IL-
33 receptor subunit, ST2, which when knocked out abrogates
resistance to EAE in the partially resistant BALB/c mouse strain.
The adoptive transfer of pMOG-specific CD4+ T cells from
ST2+/+ mice were unable to induce EAE in ST2−/− mice
indicating signaling through the IL-33 receptor on CD4+ T
cells is suppressive in the EAE model (49). In the case of F.
hepatica ES (FHES), administration induced Th2 responses, but
disease protection was independent of IL-4, IL-10 and Tregs,
although it was IL-33-dependent and the transfer of FHES-
induced eosinophils conferred protection in the EAEmodel (50).
Together these studies suggest that in some helminth infection
models signaling through IL-33 may be essential for EAE disease
protection. In the current study we identified that both HES and
infection with H. polygyrus induced ST2 expression on CD4+ T
cells and interestingly in the IL-4Rα−/− mice, which were not
protected with H. polygyrus, there was very little expression of
ST2 suggesting that IL-33 signaling may also play a role in EAE
protection in this model.
The programmed cell-death (PD)-1/PD-L1 pathway is
extensively studied in cancer research; however this tolerogenic
pathway is also critical for maintaining homeostasis and deficits
can lead to the development of autoimmunity. Binding of PD-
1 on the surface of T cells with its ligands, PD-L1 or PD-L2
which are widely expressed on both haematopoetic and non-
haematopoetic cell types, suppresses T cell activation and in the
presence of TGF-β may promote de novo generation of Tregs
(51). Therefore, expression of PD-1 and PD-L1/PD-L2 during
helminth infection may result in suppressed T cell responses
which is not only beneficial for the host but may also suppress
bystander inflammatory diseases such as EAE. In the current
study, CD4+ T cells from H. polygyrus infected and HES-
treated mice expressed higher levels of PD-1 compared to control
EAE mice, indicating that expression of this marker may also
contribute to the disease suppression seen. It is important to note
however that PD-1 expression was also elevated in H. polygyrus-
infected IL-4Rα−/− mice, but these animals were not significantly
protected from EAE, indicating that PD-1 expression may only
have a small role in the mechanism of H. polygyrus.
The CNS is now recognized to have a close relationship with
the gastrointestinal tract, and therefore helminth infections
within the gut may disrupt the normal gut-brain axis and
interfere with disease progression in a more indirect manner.
Studies have shown that alteration of the gut microbiota
can have profound effects on EAE disease development,
with antibiotic-mediated depletion of intestinal microbes
impairing the development of EAE through an IL-10-dependent
mechanism (52). These results indicate that changes in the
gut can have striking effects on CNS disease development
and also be mediated through an alteration in the peripheral
immune response. There are also significant changes to the
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gut microbiota with H. polygyrus infection (53–55), which are
unlikely to recur with the systemic administration of ES products,
further contributing to the requirement for live infection for
amelioration of disease. In our study withH. polygyrus this could
also be one of the key differences in the level of disease protection
seen with HES compared to infection.
In conclusion our study has further supported work by other
researchers assessing the effect of intestinal helminths in the
amelioration of an animal model of MS. Notably, we identified
that infection with H. polygrus was able to suppress EAE in
an IL-Rα-dependent manner, with further evidence to suggest
that a lack of IL-4 signaling also ablates any disease protection
mediated through the IL-33/ST2 receptor. Perhaps surprisingly,
it was found that ES products from H. polygyrus were unable
to mimic disease protection seen with live infection unlike
results from other helminths. Altogether our results indicate that
both a strong Th2 shift as well as parasite mediated damage
in the small intestine is required to ameliorate EAE with H.
polygyrus infection.
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Supplementary Figure 1 | H. polygyrus suppresses cellular infiltration in mouse
model of EAE disease. Female C57BL/6 mice were immunised for EAE on day 0
and were either left untreated (EAE), or received 200 L3 H. polygyrus larvae also
on day 0 (EAE + Hp). (A) Spinal cord CD4+ T cell infiltration at euthanisation on
day 19, relative to the number of glial cells. (B) Spinal cord macrophage infiltration
(CD11b+CD45hi cells as gated detailed in Supplementary Figure 2) at
euthanisation on day 19, relative to the number of glial cells. Data are pooled from
two independent experiments, with a total n = 10, and show arithmetic means
and standard errors. Data were analyzed by Mann-Whitney nonparametric test
(C,D), ∗p < 0.05.
Supplementary Figure 2 | Gating strategy for spinal cord infiltrating
macrophages. Female C57BL/6 mice were immunized for EAE on day 0 and were
either left untreated (EAE), or received 200 L3 H. polygyrus larvae also on day 0
(EAE + Hp). Within the gate of sinle live leukocytes, CD45+ spinal cord cells were
gated into non-myeloid cells (CD45+CD11b−), microglia (CD45intCD11b+) and
infiltrating macrophages (CD45+CD11b+). Further gating from non-myeloid cells
into T cells (CD3+) and finally CD4 (CD4+) and CD8 (CD8+) T cells.
Supplementary Figure 3 | Alterations in cell numbers following H. polygyrus
infection in EAE mice. Female C57BL/6 mice were immunised for EAE on day 0
and were either left untreated (EAE), or received 200 L3 H. polygyrus larvae also
on day 0 (EAE + Hp). (A) Cell numbers in draining inguinal lymph nodes (LNs),
measured by flow cytometry at euthanisation on day 19. (B) Cell numbers in
spleen, measured by flow cytometry at euthanisation on day 19. All data are in (A)
are from a single experiment (n = 5/group) and in (B) pooled from two
independent experiments, with a total n = 10/group, and shown are the means ±
SEM; (B) was statistically analysed by unpaired t-test with Welch’s correction for
unequal variances, ∗p < 0.05, ∗∗p < 0.01.
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